These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20861598)

  • 21. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium.
    Goff DC; Bertoni AG; Kramer H; Bonds D; Blumenthal RS; Tsai MY; Psaty BM
    Circulation; 2006 Feb; 113(5):647-56. PubMed ID: 16461837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents.
    Liberman JN; Berger JE; Lewis M
    Arch Pediatr Adolesc Med; 2009 Apr; 163(4):357-64. PubMed ID: 19349565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention.
    Carrington MJ; Retegan C; Johnston CI; Jennings GL; Stewart S
    J Clin Nurs; 2009 Mar; 18(5):678-86. PubMed ID: 19077020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidemia and lipid-lowering therapy in the elderly.
    Deedwania P; Volkova N
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):453-63. PubMed ID: 15889973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke.
    Muntner P; DeSalvo KB; Wildman RP; Raggi P; He J; Whelton PK
    Am J Epidemiol; 2006 May; 163(10):913-20. PubMed ID: 16597707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.
    de Rojas FD; De Frutos T; Ponte A; Chacón JM; Vitale GC;
    Prev Cardiol; 2009; 12(2):65-71. PubMed ID: 19476579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
    Chapman RH; Petrilla AA; Berman L; Benner JS; Tang SS
    Am J Cardiovasc Drugs; 2009; 9(5):299-308. PubMed ID: 19791839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
    Jaussi A; Noll G; Meier B; Darioli R
    Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.
    Zhu Y; Pandya BJ; Choi HK
    Am J Med; 2012 Jul; 125(7):679-687.e1. PubMed ID: 22626509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.